STAT

In first 2020 debate, Democrats escalate their attacks on pharma and its high prices

Disparaging drug companies quickly became a defining feature of the Democratic debate on Wednesday, with candidates rushing to prove they were most willing to “take on pharma.”
Democratic presidential hopefuls ahead of the first primary debate.

WASHINGTON — Democrats demonized the pharmaceutical industry throughout the first primary debate of the 2020 presidential election, racing to prove their status as the candidate most willing to “take on pharma.”

Sen. Elizabeth Warren (Mass.) castigated “giant drug companies” for their part in “rigging” the American economy in favor of corporate interests. Sen. Amy Klobuchar (Minn.) said

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks